DHDieter Häring

Dieter Häring

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dieter Häring has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis

    by Tjalf Ziemssen, Mark S Freedman, Amit Bar-Or, Xavier Montalban, Charlotte E Teunissen, Dieter A Häring, Petra Kukkaro, Martin Merschhemke, Bernd C Kieseier, Meghana Karnik-Henry, et al.

    Background: Neurofilament light chain (NfL) is a promising marker for predicting disease activity in relapsing multiple sclerosis (RMS). To date, however, there has been no commercially available NfL assay validated in MS and intended for routine clinical use. Objective: To identify and validate a single threshold for NfL in blood that differentiates RMS patients, aged 18–55 years, at a higher versus lower risk of disease activity over 2 years, using the Atellica ® IM NfL assay. Methods: The optimal NfL threshold for this assay/use case was identified and independently validated using ASCLEPIOS I and II data, respectively. The primary endpoint (annualized number of new/enlarging T2 (neT2) lesions) was analyzed using negative binomial models. Threshold optimization used maximum likelihood methodology. Generalizability analyses used data from ASCLEPIOS II, FREEDOMS, and TRANSFORMS. Results: NfL concentration of 12.9 pg/mL was validated as the optimal cutoff for prognosticating disease activity as measured by neT2 lesion over 2 years. This threshold prognosticated individual patient risk for persistent disease activity (>3 neT2 lesions/year over 2 years) and showed prognostic value across relevant subgroups and clinical scenarios. Findings for relapses were similar. Conclusion: The CE-marked Atellica ® IM NfL assay is now validated for prognostic use in RMS patients.


  • Top Cited Papers
    Open Access

    AI-driven reclassification of multiple sclerosis progression

    by Habib Ganjgahi, Dieter A. Häring, Piet Aarden, Gordon Graham, Yang Sun, Stephen Gardiner, Wendy Su, Claude Berge, Antje Bischof, Elizabeth Fisher, et al.

    Multiple sclerosis (MS) affects 2.9 million people. Traditional classification of MS into distinct subtypes poorly reflects its pathobiology and has limited value for prognosticating disease evolution and treatment response, thereby hampering drug discovery. Here we report a data-driven classification of MS disease evolution by analyzing a large clinical trial database (approximately 8,000 patients, 118,000 patient visits and more than 35,000 magnetic resonance imaging scans) using probabilistic machine learning. Four dimensions define MS disease states: physical disability, brain damage, relapse and subclinical disease activity. Early/mild/evolving (EME) MS and advanced MS represent two poles of a disease severity spectrum. Patients with EME MS show limited clinical impairment and minor brain damage. Transitions to advanced MS occur via brain damage accumulation through inflammatory states, with or without accompanying symptoms. Advanced MS is characterized by moderate to high disability levels, radiological disease burden and risk of disease progression independent of relapses, with little probability of returning to earlier MS states. We validated these results in an independent clinical trial database and a real-world cohort, totaling more than 4,000 patients with MS. Our findings support viewing MS as a disease continuum. We propose a streamlined disease classification to offer a unifying understanding of the disease, improve patient management and enhance drug discovery efficiency and precision.


  • Open Access

    BARTharm: MRI Harmonization Using Image Quality Metrics and Bayesian Non-parametric

    by Emma Prevot, Dieter A. Haering, Laura Gaetano, Russell T. Shinohara, Chris Holmes, Thomas E. Nichols, Habib Ganjgahi

    Image derived phenotypes (IDPs) harmonization from Magnetic Resonance Imaging (MRI) data is essential for reducing scanner-induced, non-biological variability and enabling accurate multi-site analysis. Existing methods like ComBat, while widely used, rely on linear assumptions and explicit scanner IDs - limitations that reduce their effectiveness in real-world scenarios involving complex scanner effects, non-linear biological variation, or anonymized data. We introduce BARTharm, a novel harmonization framework that uses Image Quality Metrics (IQMs) instead of Scanner IDs and models scanner and biological effects separately using Bayesian Additive Regression Trees (BART), allowing for flexible, data-driven adjustment of IDPs. Through extensive simulation studies, we demonstrate that IQMs provide a more informative and flexible representation of scanner-related variation than categorical Scanner IDs, enabling more accurate removal of non-biological effects. Leveraging this and its ability to model complex relationships, BARTharm, consistently outperforms ComBat across a range of challenging scenarios, including model misspecification and confounded scanner-biological relationships. Applied to real-world datasets, BARTharm successfully removes scanner-induced bias while preserving meaningful biological signals, resulting in stronger, more reliable associations with clinical outcomes. Overall, we find that BARTharm is a robust, data-driven improvement over traditional harmonization approaches, particularly suited for modern, large-scale neuroimaging studies.


  • Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials

    by David Leppert, Harald Kropshofer, Dieter Häring, Frank Dahlke, Ashwini Patil, Rolf Meinert, Davorka Tomic, Ludwig Kappos, Jens Kuhle


  • Open Access

    Blood Neurofilament Light in Progressive Multiple Sclerosis

    by David Leppert, Harald Kropshofer, Dieter A. Häring, Frank Dahlke, Ashwini Patil, Rolf Meinert, Davorka Tomic, Ludwig Kappos, Jens Kuhle

    Background and Objectives To investigate the potential of plasma neurofilament light (pNfL) as a biomarker of disease progression and treatment response in progressive multiple sclerosis (PMS) with and without acute disease activity. Methods A post hoc blinded analysis of pNfL levels in 2 placebo-controlled, phase 3 studies in secondary progressive multiple sclerosis (SPMS; EXPAND) and primary progressive multiple sclerosis (PPMS; INFORMS) using siponimod and fingolimod, respectively, as active compounds was performed. pNfL levels were quantified using a single molecule array (Homebrew Simoa) immunoassay from stored ethylenediaminetetraacetic acid (EDTA) plasma samples of all patients who consented for exploratory biomarker analysis in either study; pNfL levels were divided into high (≥30 pg/mL) and low (p < 0.0001). In both studies, higher baseline pNfL levels were associated with older age, higher Expanded Disability Status Scale score, more Gd+ lesions, and higher T2 lesion load (all p < 0.05). Independent of treatment, high vs low baseline pNfL levels were associated with significantly higher risks of confirmed 3-month (SPMS [32%], hazard ratio [95% CI] 1.32 [1.09–1.61]; PPMS [49%], 1.49 [1.05–2.12]) and 6-month disability progression (SPMS [26%], 1.26 [1.01–1.57]; PPMS [48%], 1.48 [1.01–2.17]), earlier wheelchair dependence (SPMS [50%], 1.50 [0.96–2.34]; PPMS [197%], 2.97 [1.44–6.10]), cognitive decline (SPMS [41%], 1.41 [1.09–1.84]), and higher rates of brain atrophy (mean change at month 24: SPMS, −0.92; PPMS, −1.39). Baseline pNfL levels were associated with future disability progression and the degree of brain atrophy regardless of presence or absence of acute disease activity (gadolinium-enhancing lesions or recent occurrence of relapses before baseline). pNfL levels were lower in patients treated with siponimod or fingolimod vs placebo-treated patients and higher in those having experienced disability progression. Discussion pNfL was associated with future clinical and radiologic disability progression features at the group level. pNfL was reduced by treatment and may be a meaningful outcome measure in PMS studies. Trial Registration Information EXPAND (ClinicalTrials.gov identifier: NCT01665144) and INFORMS (ClinicalTrials.gov identifier: NCT00731692).


  • Top Cited Papers
    Open Access

    How patients with multiple sclerosis acquire disability

    by Fred D Lublin, Dieter A Häring, Habib Ganjgahi, Alex Ocampo, Farhad Hatami, Jelena Čuklina, Piet Aarden, Frank Dahlke, Douglas L Arnold, Heinz Wiendl, et al.

    Patients with multiple sclerosis acquire disability either through relapse-associated worsening (RAW) or progression independent of relapse activity (PIRA). This study addresses the relative contribution of relapses to disability worsening over the course of the disease, how early progression begins and the extent to which multiple sclerosis therapies delay disability accumulation. Using the Novartis-Oxford multiple sclerosis (NO.MS) data pool spanning all multiple sclerosis phenotypes and paediatric multiple sclerosis, we evaluated ∼200 000 Expanded Disability Status Scale (EDSS) transitions from >27 000 patients with ≤15 years follow-up. We analysed three datasets: (i) A full analysis dataset containing all observational and randomized controlled clinical trials in which disability and relapses were assessed (n = 27 328); (ii) all phase 3 clinical trials (n = 8346); and (iii) all placebo-controlled phase 3 clinical trials (n = 4970). We determined the relative importance of RAW and PIRA, investigated the role of relapses on all-cause disability worsening using Andersen-Gill models and observed the impact of the mechanism of worsening and disease-modifying therapies on the time to reach milestone disability levels using time continuous Markov models. PIRA started early in the disease process, occurred in all phenotypes and became the principal driver of disability accumulation in the progressive phase of the disease. Relapses significantly increased the hazard of all-cause disability worsening events; following a year in which relapses occurred (versus a year without relapses), the hazard increased by 31–48% (all P < 0.001). Pre-existing disability and older age were the principal risk factors for incomplete relapse recovery. For placebo-treated patients with minimal disability (EDSS 1), it took 8.95 years until increased limitation in walking ability (EDSS 4) and 18.48 years to require walking assistance (EDSS 6). Treating patients with disease-modifying therapies delayed these times significantly by 3.51 years (95% confidence limit: 3.19, 3.96) and 3.09 years (2.60, 3.72), respectively. In patients with relapsing-remitting multiple sclerosis, those who worsened exclusively due to RAW events took a similar length of time to reach milestone EDSS values compared with those with PIRA events; the fastest transitions were observed in patients with PIRA and superimposed relapses. Our data confirm that relapses contribute to the accumulation of disability, primarily early in multiple sclerosis. PIRA begins in relapsing-remitting multiple sclerosis and becomes the dominant driver of disability accumulation as the disease evolves. Pre-existing disability and older age are the principal risk factors for further disability accumulation. The use of disease-modifying therapies delays disability accrual by years, with the potential to gain time being highest in the earliest stages of multiple sclerosis.


  • Open Access

    Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis

    by Jennifer S. Graves, Marius Thomas, Jun Li, Anuja R. Shah, Alexandra Goodyear, Markus R. Lange, Heinz Schmidli, Dieter A. Häring, Tim Friede, Jutta Gärtner

    Background: To support innovative trial designs in a regulatory setting for pediatric-onset multiple sclerosis (MS), the study aimed to perform a systematic literature review and meta-analysis of relapse rates with interferon β (IFN β), fingolimod, and natalizumab and thereby demonstrate potential benefits of Bayesian and non-inferiority designs in this population. Methods: We conducted a literature search in MEDLINE and EMBASE from inception until 17 June 2020 of all studies reporting annualized relapse rates (ARR) in IFN β-, fingolimod-, or natalizumab-treated patients with pediatric-onset relapsing–remitting MS. These interventions were chosen because the literature was mainly available for these treatments, and they are currently used for the treatment of pediatric MS. Two researchers independently extracted data and assessed study quality using the Cochrane Effective Practice and Organization of Care – Quality Assessment Tool. The meta-analysis estimates were obtained by Bayesian random effects model. Data were summarized as ARR point estimates and 95% credible intervals. Results: We found 19 articles, including 2 randomized controlled trials. The baseline ARR reported was between 1.4 and 3.7. The meta-analysis-based ARR was significantly higher in IFN β-treated patients (0.69, 95% credible interval: 0.51–0.91) versus fingolimod (0.11, 0.04–0.27) and natalizumab (0.17, 0.09–0.31). Based on the meta-analysis results, an appropriate non-inferiority margin versus fingolimod could be in the range of 2.29–2.67 and for natalizumab 1.72–2.29 on the ARR ratio scale. A Bayesian design, which uses historical information for a fingolimod or natalizumab control arm, could reduce the sample size of a new trial by 18 or 14 patients, respectively. Conclusion: This meta-analysis provides evidence that relapse rates are considerably higher with IFNs versus fingolimod or natalizumab. The results support the use of innovative Bayesian or non-inferiority designs to avoid exposing patients to less effective comparators in trials and bringing new medications to patients more efficiently.


  • Open Access

    Application of a convolutional neural network to the quality control of MRI defacing

    by Daniel J. Delbarre, Luis Santos, Habib Ganjgahi, Neil Horner, Aaron McCoy, Henrik Westerberg, Dieter A. Häring, Thomas E. Nichols, Ann-Marie Mallon

    Large-scale neuroimaging datasets present unique challenges for automated processing pipelines. Mo-tivated by a large clinical trials dataset of Multiple Sclerosis with over 235,000 MRI scans, we consider the challenge of defacing - anonymisation to remove identifying facial features. The defacing process must undergo quality control (QC) checks to ensure that the facial features have been adequately anonymised and that the brain tissue is left completely intact. Visual QC checks – particularly on a project of this scale – are time-consuming and can cause delays in preparing data. We have developed a convolutional neural network (CNN) that can assist with the QC of the application of MRI defacing; our CNN is able to distinguish between scans that are correctly defaced, and can also classify defacing failures into three sub-types to facilitate parameter tuning during remedial re-defacing. Since integrating the CNN into our anonymisation pipeline, over 75,000 scans have been processed. Strict thresholds have been applied so that ambiguous classifications are referred for visual QC checks, however all scans still undergo a time-efficient verification check before being marked as passed. After applying the thresholds, our network is 92% accurate and is able to classify nearly half of the scans without the need for protracted manual checks. Even with the introduction of the verification checks, incorporation of the CNN has reduced the time spent undertaking QC checks by 42% during initial defacing, and by 35% overall. With the help of the CNN, we have been able to successfully deface 96% of the scans in the project whilst maintaining high QC standards. In a similarly sized new project of this scale, we would expect the model to reduce the time spent on manual QC checks by 125 hours. Our approach is applicable to other projects with the potential to greatly improve the efficiency of imaging anonymisation pipelines.

  • MRI Parameters as Predictors of Long-Term Disease Outcome Over 8 Years in RRMS Patients (S51.008)

    by Douglas Jeffery, Daniela Piani Meier, Davorka Tomic, Dieter Häring, Timothy Vollmer

  • Open Access

    BRAIN VOLUME CHANGE AND DISABILITY IN FINGOLIMOD TRIALS

    by Richard Nicholas, Frederik Barkhof, Jeffrey Cohen, Ernst-Willhelm Radue, Ludwig Kappos, Dieter Häring, Nikolaos Sfikas, Philipp von Rosenstiel, Gordon Francis

    Objective Investigate relationships between Brain Volume (BV) loss and clinical and MRI outcomes observed in three phase 3 fingolimod trials. Method Percentage BV change (PBVC) was measured in the core-phases and extensions of FREEDOMS, FREEDOMS II and TRANSFORMS using ‘Structural Image Evaluation Normalization, of Atrophy’. During the core-phases, correlations were assessed between PBVC and: cumulative Gd+-lesion count (LC); T2-lesion volume change (LVC);new/enlarging T2-LC; T1-hypointense LVC; number of confirmed relapses; EDSS score change; and MSFC score change. Proportions of patients with 3- or 6-month confirmed disability progression (CDP) and correlations between PBVC and EDSS were determined. Results In FREEDOMS, FREEDOMS II and TRANSFORMS, PBVC consistently correlated best with cumulative Gd+-LC(pConclusion BV loss was greatest in patients who relapsed or who developed new Gd+ or T2-lesions. By reducing BV loss, fingolimod may slow disability progression.